Baird Medical Showcases Advanced MWA Technology with UCSF Expert in Guangzhou and Shenzhen
Baird Medical (NASDAQ: BDMD) hosted Dr. Quan-Yang Duh, Chief of Endocrine Surgery at UCSF, for a clinical observation visit in Guangzhou and Shenzhen, China. The visit showcased Baird Medical's microwave ablation (MWA) technology in action.
At Sun Yat-sen University Cancer Center, Dr. Duh observed several thyroid ablation cases, including a notable procedure performed by Dr. Feng Han treating bilateral thyroid nodules with a 4 cm lesion. The procedure demonstrated the minimally invasive nature of the MWA system, with the patient remaining awake throughout.
In Shenzhen, Dr. Duh observed additional MWA procedures and delivered a presentation on surgical management of thyroid diseases. The visit included academic discussions with specialists about integrating microwave ablation with surgical approaches.
Baird Medical (NASDAQ: BDMD) ha ospitato il Dr. Quan-Yang Duh, Capo della Chirurgia Endocrina presso UCSF, per una visita di osservazione clinica a Guangzhou e Shenzhen, Cina. La visita ha messo in evidenza la tecnologia di ablazione a microonde (MWA) di Baird Medical in azione.
Presso il Centro Oncologico dell'Università Sun Yat-sen, il Dr. Duh ha osservato diversi casi di ablazione della tiroide, incluso un intervento notevole eseguito dal Dr. Feng Han che ha trattato noduli tiroidei bilaterali con una lesione di 4 cm. La procedura ha dimostrato la natura minimamente invasiva del sistema MWA, con il paziente che è rimasto sveglio durante l'intervento.
A Shenzhen, il Dr. Duh ha osservato ulteriori procedure MWA e ha tenuto una presentazione sulla gestione chirurgica delle malattie tiroidee. La visita ha incluso discussioni accademiche con specialisti sull'integrazione dell'ablazione a microonde con approcci chirurgici.
Baird Medical (NASDAQ: BDMD) recibió al Dr. Quan-Yang Duh, Jefe de Cirugía Endocrina en UCSF, para una visita de observación clínica en Guangzhou y Shenzhen, China. La visita mostró la tecnología de ablación por microondas (MWA) de Baird Medical en acción.
En el Centro Oncológico de la Universidad Sun Yat-sen, el Dr. Duh observó varios casos de ablación de tiroides, incluyendo un procedimiento notable realizado por el Dr. Feng Han que trató nódulos tiroideos bilaterales con una lesión de 4 cm. El procedimiento demostró la naturaleza mínimamente invasiva del sistema MWA, con el paciente permaneciendo despierto durante todo el proceso.
En Shenzhen, el Dr. Duh observó procedimientos adicionales de MWA y presentó una charla sobre el manejo quirúrgico de las enfermedades tiroideas. La visita incluyó discusiones académicas con especialistas sobre la integración de la ablación por microondas con enfoques quirúrgicos.
Baird Medical (NASDAQ: BDMD)는 UCSF의 내분비외과장인 Dr. Quan-Yang Duh를 초대하여 중국 광저우와 선전에서 임상 관찰 방문을 진행했습니다. 이 방문은 Baird Medical의 마이크로웨이브 절제(MWA) 기술을 실제로 보여주었습니다.
선전대학 암센터에서 Dr. Duh는 여러 갑상선 절제 사례를 관찰했으며, 특히 4cm 병변을 가진 양측 갑상선 결절을 치료하는 Dr. Feng Han의 주목할 만한 절차를 보았습니다. 이 절차는 MWA 시스템의 최소 침습적 특성을 보여주었으며, 환자는 절차 내내 깨어 있었습니다.
선전에서 Dr. Duh는 추가 MWA 절차를 관찰하고 갑상선 질환의 외과적 관리에 대한 발표를 하였습니다. 이 방문은 전문가들과 마이크로웨이브 절제를 외과적 접근 방식과 통합하는 것에 대한 학술적 논의도 포함되었습니다.
Baird Medical (NASDAQ: BDMD) a accueilli le Dr Quan-Yang Duh, Chef de la Chirurgie Endocrinienne à l'UCSF, pour une visite d'observation clinique à Guangzhou et Shenzhen, en Chine. La visite a mis en avant la technologie d'ablation par micro-ondes (MWA) de Baird Medical en action.
Au Centre de Cancérologie de l'Université Sun Yat-sen, le Dr Duh a observé plusieurs cas d'ablation de la thyroïde, y compris une procédure notable réalisée par le Dr Feng Han traitant des nodules thyroïdiens bilatéraux avec une lésion de 4 cm. La procédure a démontré la nature peu invasive du système MWA, le patient restant éveillé tout au long de l'intervention.
À Shenzhen, le Dr Duh a observé d'autres procédures MWA et a donné une présentation sur la gestion chirurgicale des maladies de la thyroïde. La visite a inclus des discussions académiques avec des spécialistes sur l'intégration de l'ablation par micro-ondes avec des approches chirurgicales.
Baird Medical (NASDAQ: BDMD) hat Dr. Quan-Yang Duh, Leiter der Endokrinen Chirurgie an der UCSF, zu einem klinischen Beobachtungsbesuch in Guangzhou und Shenzhen, China, eingeladen. Der Besuch stellte die Mikrowellenablationstechnologie (MWA) von Baird Medical in Aktion vor.
Am Krebszentrum der Sun Yat-sen-Universität beobachtete Dr. Duh mehrere Fälle von Schilddrüsenablation, einschließlich eines bemerkenswerten Verfahrens, das von Dr. Feng Han durchgeführt wurde, um bilaterale Schilddrüsenknoten mit einer Läsion von 4 cm zu behandeln. Das Verfahren demonstrierte die minimal-invasive Natur des MWA-Systems, wobei der Patient während des gesamten Eingriffs wach blieb.
In Shenzhen beobachtete Dr. Duh weitere MWA-Verfahren und hielt eine Präsentation über das chirurgische Management von Schilddrüsenerkrankungen. Der Besuch umfasste akademische Diskussionen mit Spezialisten über die Integration der Mikrowellenablation mit chirurgischen Ansätzen.
- Successful demonstration of MWA technology's precision and efficiency in treating complex thyroid cases
- Strategic partnership with prestigious medical institutions in China
- Validation of technology by renowned UCSF endocrine surgery expert
- None.
In
"The case was highly educational," said Dr. Duh. "Dr. Han demonstrated exceptional expertise, and the speed and accuracy of the procedure highlight both the skill of the medical team and the medical team and the sophistication of the technology." Following the procedure, Dr. Duh engaged in in-depth academic discussions with Dr. Feng Han and Dr. Jian Hua Zhou, Chief of Interventional Radiology at Sun Yat-sen University Cancer Center, further fostering international collaboration in thyroid ablation advancements.
Dr. Duh continued his visit in
"We are honored to facilitate these global academic exchanges and showcase the clinical impact of our MWA technology," said Haimei Wu, Chairwoman of Baird Medical. "As we continue to expand, we remain committed to driving innovation and working alongside top-tier medical professionals to enhance the accessibility and precision of minimally invasive thyroid treatments."
As Baird Medical continues its global expansion, the Company remains dedicated to pioneering advancements in microwave ablation technology and forging strategic partnerships that redefine the future of thyroid care.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-advanced-mwa-technology-with-ucsf-expert-in-guangzhou-and-shenzhen-302418226.html
SOURCE BDMD
FAQ
What were the key outcomes of Dr. Duh's observation of BDMD's MWA technology in China?
How did BDMD's MWA technology perform in treating thyroid nodules at Sun Yat-sen University Cancer Center?
What medical institutions did BDMD partner with for the MWA technology demonstration in China?
What was the focus of Dr. Duh's presentation during the BDMD event in Shenzhen?
